|
Nektar Therapeutics has pegged its fortunes to making drugs more effective. The drug development firm creates pharmaceuticals using PEGylation technology, which enhances the performance of existing drugs by reducing immune response, allowing for longer-term treatment. It currently has two cancer compounds in trials, as well as an oral pain medication, and it partners with Bayer HealthCare on two anti-infective drugs that are in trials. Nektar receives royalties on inhaled Ciprofloxacin powder, also developed with Bayer, as well as on nine other products made with partners including Amgen, Roche, and Schering-Plough. Nektar has about 15 products in its pipeline.
|
| | | Contact Information | |
Address: |
201 Industrial Rd.
San Carlos, CA 94070
| | Phone: | 650-631-3100 | | Fax: | 650-631-3150 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 90.20 M | | Revenue Growth (1 yr): | (-67.00%) | | Employees (2008): | 338 | | Employee Growth (1 yr): | (-41.20%) |
|
|
Key People
| | • |
Chairman:
Robert B. Chess
| | • |
President, CEO, and Director:
Howard W. Robin
| | • |
SVP and COO:
Bharat M. Chowrira
|
|
|
